Genome-wide CRISPR-Cas9 knockout screens have emerged as a powerful method for identifying key genes driving tumor growth. The aim of this study was to explore the phagocytosis regulators (PRs) specifically associated with lower-grade glioma (LGG) using the CRISPR-Cas9 screening database. Identifying these core PRs could lead to novel therapeutic targets and pave the way for a non-invasive radiogenomics approach to assess LGG patients’ prognosis and treatment response. We selected 24 PRs that were overexpressed and lethal in LGG for analysis. The identified PR subtypes (PRsClusters, geneClusters, and PRs-score models) effectively predicted clinical outcomes in LGG patients. Immune response markers, such as CTLA4, were found to be significantly associated with PR-score. Nine radiogenomics models using various machine learning classifiers were constructed to uncover survival risk. The area under the curve (AUC) values for these models in the test and training datasets were 0.686 and 0.868, respectively. The CRISPR-Cas9 screen identified novel prognostic radiogenomics biomarkers that correlated well with the expression status of specific PR-related genes in LGG patients. These biomarkers successfully stratified patient survival outcomes and treatment response using The Cancer Genome Atlas (TCGA) database. This study has important implications for the development of precise clinical treatment strategies and holds promise for more accurate therapeutic approaches for LGG patients in the future.
GittlemanHSloanAEBarnholtz-SloanJS.An independently validated survival nomogram for lower-grade glioma. Neuro Oncol2020;22:665–74
2.
LiuZJiHFuWMaSZhaoHWangFDongJYanXZhangJWangNWuJHuS.IGFBPs were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma. Front Endocrinol2022;13:943300
3.
SunYSedgwickAJPalarasahYMangiolaSBarrowAD.A transcriptional signature of PDGF-DD activated natural killer cells predicts more favorable prognosis in low-grade glioma. Front Immunol2021;12:668391
4.
GarginiRSegura-CollarBHerránzBGarcía-EscuderoVRomero-BravoANúñezFJGarcía-PérezDGutiérrez-GuamánJAyuso-SacidoASeoaneJPérez-NúñezASepúlveda-SánchezJMHernández-LaínACastroMGGarcía-EscuderoRÁvilaJSánchez-GómezP.The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Sci Transl Med2020;12:eaax1501
5.
Van den BentMJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol2014;16:1570–4
6.
YoshiharaKShahmoradgoliMMartínezEVegesnaRKimHTorres-GarciaWTreviñoVShenHLairdPWLevineDACarterSLGetzGStemke-HaleKMillsGBVerhaakRGW. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun2013;4:2612
7.
GePLLiSFWangWWLiCBFuYBFengZKLiLZhangGGaoZQDangXWWuY.Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma. Aging2020;12:5479–99
8.
NgambenjawongCGustafsonHHPunSH.Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev2017;114:206–21
9.
YanSWanG.Tumor-associated macrophages in immunotherapy. FEBS J2021;288:6174–86
10.
DeNardoDGRuffellB.Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol2019;19:369–82
11.
CassettaLPollardJW.Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov2018;17:887–904
12.
BiswasSKMantovaniA.Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol2010;11:889–96
PathriaPLouisTLVarnerJA.Targeting tumor-associated macrophages in cancer. Trends Immunol2019;40:310–27
15.
MiaoLQiJZhaoQWuQNWeiDLWeiXLLiuJChenJZengZLJuHQLuoHYXuRH.Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells. Theranostics2020;10:498–515
16.
LogtenbergMEWScheerenFASchumacherTN. The CD47-SIRPα immune checkpoint. Immunity2020;52:742–52
17.
GordonSRMauteRLDulkenBWHutterGGeorgeBMMcCrackenMNGuptaRTsaiJMSinhaRCoreyDRingAMConnollyAJWeissmanIL.PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature2017;545:495–9
18.
MantovaniAMarchesiFMalesciALaghiLAllavenaP.Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol2017;14:399–416
19.
KocakBDurmazESAtesESelITurgut GunesSKayaOKZeynalovaAKilickesmezO.Radiogenomics of lower-grade gliomas: machine learning-based MRI texture analysis for predicting 1p/19q codeletion status. Eur Radiol2020;30:877–86
20.
BeerLSahinHBatemanNWBlazicIVargasHAVeeraraghavanHKirbyJFevrier-SullivanBFreymannJBJaffeCCBrentonJMiccóMNougaretSDarcyKMMaxwellGLConradsTPHuangESalaE.Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. Eur Radiol2020;30:4306–16
21.
KimMJungSYParkJEJoYParkSYNamSJKimJHKimHS.Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. Eur Radiol2020;30:2142–51
22.
ZhangJZhaoXZhaoYZhangJZhangZWangJWangYDaiMHanJ.Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging2020;47:1137–46
23.
WeiJYangGHaoXGuDTanYWangXDongDZhangSWangLZhangHTianJ.A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. Eur Radiol2019;29:877–88
24.
YangLGuDWeiJYangCRaoSWangWChenCDingYTianJZengM.A radiomics nomogram for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Liver Cancer2019;8:373–86
25.
HuLSNingSEschbacherJMBaxterLCGawNRanjbarSPlasenciaJDueckACPengSSmithKANakajiPKarisJPQuarlesCCWuTLoftusJCJenkinsRBSicotteHKollmeyerTMO’NeillBPElmquistWHoxworthJMFrakesDSarkariaJSwansonKRTranNLLiJMitchellJR.Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol2017;19:128–37
26.
PennisiE.The CRISPR craze. Science2013;341:833–6
27.
ChenMMaoAXuMWengQMaoJJiJ.CRISPR-Cas9 for cancer therapy: opportunities and challenges. Cancer Lett2019;447:48–55
28.
CongLRanFACoxDLinSBarrettoRHabibNHsuPDWuXJiangWMarraffiniLAZhangF.Multiplex genome engineering using CRISPR/Cas systems. Science2013;339:819–23
29.
MaliPYangLEsveltKMAachJGuellMDiCarloJENorvilleJEChurchGM.RNA-guided human genome engineering via Cas9. Science2013;339:823–6
30.
ZhanTRindtorffNBetgeJEbertMPBoutrosM.CRISPR/Cas9 for cancer research and therapy. Semin Cancer Biol2019;55:106–19
31.
ZhengNLiLWangX.Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems. Clin Transl Med2020;10:412–26
32.
QiLSLarsonMHGilbertLADoudnaJAWeissmanJSArkinAPLimWA.Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell2013;152:1173–83
33.
Perez-PineraPKocakDDVockleyCMAdlerAFKabadiAMPolsteinLRThakorePIGlassKAOusteroutDGLeongKWGuilakFCrawfordGEReddyTEGersbachCA.RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods2013;10:973–6
34.
GilbertLALarsonMHMorsutLLiuZBrarGATorresSEStern-GinossarNBrandmanOWhiteheadEHDoudnaJALimWAWeissmanJSQiLS.CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell2013;154:442–51
35.
KamberRANishigaYMortonBBanuelosAMBarkalAAVences-CatalánFGuMFernandezDSeoaneJAYaoDLiuKLinSSpeesKCurtisCJerby-ArnonLWeissmanILSageJBassikMC.Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature2021;597:549–54
36.
MeyersRMBryanJGMcFarlandJMWeirBASizemoreAEXuHDhariaNVMontgomeryPGCowleyGSPantelSGoodaleALeeYAliLDJiangGLubonjaRHarringtonWFStricklandMWuTHawesDCZhivichVAWyattMRKalaniZChangJJOkamotoMStegmaierKGolubTRBoehmJSVazquezFRootDEHahnWCTsherniakA.Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet2017;49:1779–84
37.
YeYXiangYOzgucFMKimYLiuCJParkPKHuQDiaoLLouYLinCGuoAYZhouBWangLChenZTakahashiJSMillsGBYooSHHanL.The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst2018;6:314.e2–28.e2
38.
RordenCBrettM.Stereotaxic display of brain lesions. Behav Neurol2000;12:191–200
39.
ZhangLGiusteFVizcarraJCLiXGutmanD.Radiomics features predict CIC mutation status in lower grade glioma. Front Oncol2020;10:937
40.
Van GriethuysenJJMFedorovAParmarCHosnyAAucoinNNarayanVBeets-TanRGHFillion-RobinJCPieperSAertsH.Computational radiomics system to decode the radiographic phenotype. Cancer Res2017;77:e104–7
41.
SongYZhangJZhangYDHouYYanXWangYZhouMYaoYFYangG.FeAture Explorer (FAE): a tool for developing and comparing radiomics models. PLoS One2020;15:e0237587
42.
LocatiMCurtaleGMantovaniA.Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol2020;15:123–47
43.
RaggiFPelassaSPierobonDPencoFGattornoMNovelliFEvaAVaresioLGiovarelliMBoscoMC.Regulation of human macrophage M1-M2 polarization balance by hypoxia and the triggering receptor expressed on myeloid cells-1. Front Immunol2017;8:1097
44.
GrothCHuXWeberRFlemingVAltevogtPUtikalJUmanskyV.Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer2019;120:16–25
45.
LimJJGrinsteinSRothZ.Diversity and versatility of phagocytosis: roles in innate immunity, tissue remodeling, and homeostasis. Front Cell Infect Microbiol2017;7:191
46.
GordonS.Phagocytosis: an immunobiologic process. Immunity2016;44:463–75
47.
FreemanSAGrinsteinS.Phagocytosis: receptors, signal integration, and the cytoskeleton. Immunol Rev2014;262:193–215
48.
OrecchioniMGhoshehYPramodABLeyK.Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol2019;10:1084
49.
KumariNChoiSH.Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res2022;41:68
50.
MorgensDWDeansRMLiABassikMC.Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nat Biotechnol2016;34:634–6
51.
OnishiIYamamotoKKinowakiYKitagawaMKurataM.To discover the efficient and novel drug targets in human cancers using CRISPR/Cas screening and databases. Int J Mol Sci2021;22:12322
52.
SanjanaNEShalemOZhangF.Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods2014;11:783–4
53.
ChenFZhuangXLinLYuPWangYShiYHuGSunY.New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med2015;13:45
54.
WangJLuoJWenZWangXShuaiLZhongGWangCSunZChenWGeJLiuRWangXBuZ.Alpha-soluble NSF attachment protein prevents the cleavage of the SARS-CoV-2 spike protein by functioning as an interferon-upregulated furin inhibitor. mBio2022;13:e0244321
55.
AndreevaAVKutuzovMAVoyno-YasenetskayaTA.A ubiquitous membrane fusion protein alpha SNAP: a potential therapeutic target for cancer, diabetes and neurological disorders?Expert Opin Ther Targets2006;10:723–33
56.
FanFWilliamsHJBoyerJGGrahamTLZhaoHLehrRQiHSchwartzBRaushelFMMeekTD.On the catalytic mechanism of human ATP citrate lyase. Biochemistry2012;51:5198–211
57.
IcardPWuZFournelLCoquerelALincetHAlifanoM.ATP citrate lyase: a central metabolic enzyme in cancer. Cancer Lett2020;471:125–34
58.
BurkeACHuffMW.ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr Opin Lipidol2017;28:193–200
59.
QianXHuJZhaoJChenH.ATP citrate lyase expression is associated with advanced stage and prognosis in gastric adenocarcinoma. Int J Clin Exp Med2015;8:7855–60
ChenYLiKGongDZhangJLiQZhaoGLinP.ACLY: a biomarker of recurrence in breast cancer. Pathol Res Pract2020;216:153076
62.
WenJMinXShenMHuaQHanYZhaoLLiuLHuangGLiuJZhaoX.ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res2019;38:401
63.
De MagistrisP. The great escape: mRNA export through the nuclear pore complex. Int J Mol Sci2021;22:11767
64.
RousselMSauleSLagrouCRommensCBeugHGrafTStehelinD.Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature1979;281:452–5
65.
VennstromBSheinessDZabielskiJBishopJM.Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol1982;42:773–9
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
